Gemma Estrada Bertran’s Post

📖 Digital Biomarkers: Transforming Personalized Healthcare 📢 Excited to announce a new post on the Ferrer4Future blog exploring the advancing and innovative world of digital biomarkers. These tools are changing how we diagnose, monitor, and treat diseases, offering unprecedented precision and personalization for patients. In the blog we give an overview of: ✅ What are digital biomarkers ✅ Their potential applications in clinical trials, disease management, and early diagnosis ✅ Current and future challenges, including data privacy, regulations, and user engagement ✅ Key milestones showcasing the growing adoption of digital measures in clinical research This is a field thriving with potential 🚀 If you're working on innovative solutions in this space, we'd love to connect! Read the full post here: https://lnkd.in/g6piD_dJ #digitalhealth #digitalbiomarkers #innovation #Ferrer4Future #FerrerForGood Gemma Estrada Bertran, Gemma Vilajosana

Digital biomarkers are a thriving area of innovation in healthcare, from integration into clinical endpoints through to monitoring and disease management within routine care. The potential for its use as a catalyst to transform patient pathways is immense and deserves widespread focus and investment. We very much enjoyed reading this recent post from Guilherme Meneses and team at #ferrerforfuture - one such company who are prioritising collaboration to innovate in this area. Whilst the industry focus is loaded towards clinical trials at present, the use of digital biomarkers in routine care play a huge role in driving patient-centred care and enriching clinician insight to support responsive decision-making. But how can we better connect in trial and real-world applications to elevate the potential for digital biomarkers across healthcare systems? #digitalbiomarkers #pathwayinnovation #patientcentredcare #healthcareinnovation #pharmapartnerships #healthcaretechnology

Hello community! Check out the latest post on the Ferrer4Future blog, where we dive into the fascinating world of ✨digital biomarkers✨ .  These revolutionary tools are transforming how we diagnose, monitor, and treat diseases with unparalleled precision and personalization. What do you think? We'd love to hear your thoughts and experiences in this field! #digitalhealth #digitalbiomarkers #innovation #Ferrer4Future #FerrerForGood

Exciting developments are happening in the Biotech Healthcare sector! Our latest article, "Is AI Revolutionising Early Disease Detection in the Biotech Healthcare Sector?" touches on the fascinating role that AI is playing in early disease prevention and detection. We caught up with Cyted, an inspiring company that provides digital diagnostic infrastructure to enable earlier disease detection. Their use of AI and novel biomarkers to unlock clinical insights is truly remarkable. Cyted is empowering the healthcare sector to move from disease treatment to disease prevention, which is a game-changer! We also have a conversation with the dynamic founders of Cyted, Marcel Gehrung, PhD, about their journey and vision—making the healthcare sector more proactive than reactive. Read our comprehensive article on what could be the future of Biotech Healthcare! 👉 https://UKT.news/?p=12854 #HealthcareInnovation #Biotechnology #AI #EarlyDiseaseDetection #Cyted

Overcoming the forgotten hurdle: user-friendliness for digital biomarkers. Explore the importance of creating simple and effortless experiences for patients and care providers to ensure the successful integration of digital biomarkers in healthcare. #mSafety #Sony #digitalbiomarkers #healthtech

Allis.Health #DigitalOncology "Week in a Minute!" Video 🎥 In this quick teaser, we're putting the spotlight on collaborations between: 🤝 Aptar Digital Health and Gerresheimer : Aptar Digital Health and Gerresheimer join hands to develop a tailored solution to support patients and health care professionals in cancer therapy management. By seamlessly integrating Aptar Digital Health’s exclusive SaMD platform with Gx SensAir, Gerresheimer’s on-body device for subcutaneous delivery of large biologic molecules, this collaborative effort is dedicated to elevating treatment adherence and improving clinical outcomes. The strategic synergy goes beyond simplifying remote patient monitoring; it also aims to streamline the onboarding process for patients initiating new therapies, empowering them to adeptly manage potential adverse effects. 🌐 MSD and Owkin's : Pharma group MSD teams up with Owkin to pioneer artificial intelligence-powered digital pathology diagnostics that could be used to identify patients suitable for immunotherapies. These tools aim to empower pathologists and oncologists in assessing microsatellite instability-high (MSI-H) tumors. MSI-H tumors serve as critical indicators of a cell's inability to correct replication errors during DNA processes. “This strategic alliance with MSD is focused on improving the way patients are diagnosed and receive treatment, advancing our shared mission of supporting healthcare providers in their adoption of innovative digital diagnostics,” commented Meriem Sefta, Owkin’s Chief Diagnostics Officer. For a comprehensive view of these and more developments, subscribe or request a demo at hello@allis.health. #globalhealth #digitalhealth #marketnews #analystsviews #latesttrends

https://lnkd.in/dwmC6-D5 Discover the Power of Salivary Biomarkers! 💧🧬 Dive into the fascinating world of saliva-based diagnostics with our article. Saliva holds a treasure trove of information about your health. Explore how these biomarkers are revolutionizing healthcare. Read more at by clicking the link above 👆🏻. Don't miss this chance to uncover the secrets within your saliva! 💡 #SalivaryBiomarkers #HealthTech #GenomicMedicine

https://biofuture.com/ MTTI TO PRESENT EVATHERA, LONG-ACTING PRRT PLATFORM, AT BIOFUTURE™ 2023 West Chester, PA – Molecular Targeting Technologies,Inc Targeting Technologies, Inc. (MTTI), is presenting at BioFuture 2023 on Thursday 2:45 PM, Oct 5th, at Lotte New York Palace hotel. This year, registered, in-person attendees can view MTTI’s presentation live, and get advance access to a recorded version beginning September 1, five weeks prior to the actual event. Jianwei Xu, PhD, Chief Business Officer will introduce MTTI’s EvaThera, the first long-acting, targeted peptide receptor radionuclide therapy (PRRT) platform. PRRT delivers killing radiation directly to cancer cells using unique peptides to target biomarkers on those cancers. This class of therapeutics has seen explosive growth since 2018, projected to continue at 34% CAGR over the next decade. Chris Pak, PhD, founder and CEO of MTTI noted, “EvaThera provides next-generation efficacy for many hard-to-treat cancers. We’re excited to expose the broad BioFuture audience to our high value, long-acting PRRT platform.” Sara Demy, CEO of Demy-Colton commented, “We are delighted that Molecular Targeting Technologies, Inc. will be presenting.  BioFuture gathers today’s very best innovators, investors and business leaders to discuss the future of healthcare and potential game-changing technologies, like EvaThera, that will drive that future.” ABOUT BIOFUTURE BioFuture, produced by Demy-Colton, is a conference convening future-focused healthcare thinkers, top investors, stakeholders and cutting-edge companies to “Reimagine the Future of Healthcare”. BioFuture 2023 will be held in-person in New York City on October 4-6 at Lotte New York Palace Hotel, with a virtual access option for digital partnering and recorded content on October 10-12. BioFuture features multiple tracks of plenary sessions, presenting companies, workshops, networking, and an opportunity to schedule one-to-one meetings. BioFuture was founded by Demy-Colton, a leading life sciences and digital health events organization, with a long history of producing high-quality events that build networks between innovative life sciences companies and industry stakeholders. ABOUT Molecular Targeting Technologies, Inc.   MTTI is a clinical-stage company developing innovative targeted radiotherapeutics for rare cancers with high unmet needs. MTTI’s pipeline includes: #EBTATE® (ongoing clinical studies in neuroendocrine [“NET”]; Hürthle cell thyroid [HTC], and Nasopharyngeal [NPC] cancers) and #EBRGD for non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM).  Contacts For more information: www.evathera.com; Contact: Chris Pak, Email: cpak@mtarget.com

This home blood test technology from Entia is a brilliant example of how to help both cancer patients and healthcare providers with a thoughtfully-designed product. It has the potential to: 🤝 meaningfully engage patients in their own treatment process 🧑⚕️mitigate a shortage in trained phlebotomists who are currently needed to analyse lab test results 🌲minimise the need for expensive and environmentally damaging travel Early real-world testing at The Christie NHS Foundation Trust gives reason to be very optimistic. Just as relevant is Cancer Research UK (CRUK) pointing out that more testing is needed beyond initial regulatory approval to demonstrate that the same benefits can be reliably achieved by HealthTech products with all patients. You can’t measure everything at once, but you can and must have a plan to do so. Manufacturers who embrace post-market testing and feedback as an opportunity to continuously grow their evidence base will be best placed to improve their solution while actively increasing access for those who need it. Institution of Engineering and Technology (IET) ABHI The Academy of Medical Sciences NIHR (National Institute for Health and Care Research) NICE - National Institute for Health and Care Excellence Life Sciences Hub Wales

𝐀𝐒𝐂𝐎2024 𝐌𝐎𝐒𝐀𝐈𝐂: An 𝐀𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐈𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞-𝐁𝐚𝐬𝐞𝐝 𝐅𝐫𝐚𝐦𝐞𝐰𝐨𝐫𝐤 for Multimodal Analysis, Classification, and Personalized Prognostic Assessment in Rare Cancers, which can potentially revolutionize the field of oncology. Key Findings from MOSAIC Framework: 𝐁𝐞𝐭𝐭𝐞𝐫 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐆𝐫𝐨𝐮𝐩𝐢𝐧𝐠: The new method, leveraging advanced AI techniques, has shown to group patients with rare cancers more accurately than traditional methods. This enhanced precision allows for a deeper understanding of different patient types. 𝐈𝐦𝐩𝐫𝐨𝐯𝐞𝐝 𝐒𝐮𝐫𝐯𝐢𝐯𝐚𝐥 𝐏𝐫𝐞𝐝𝐢𝐜𝐭𝐢𝐨𝐧𝐬: AI-based approaches significantly outperform current standard practices in predicting patient survival outcomes, leading to more informed decisions and better patient care. 𝐂𝐥𝐞𝐚𝐫𝐞𝐫 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐨𝐟 𝐏𝐫𝐨𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐅𝐚𝐜𝐭𝐨𝐫𝐬: By identifying the most crucial factors influencing patient outcomes, the techniques provide consistent insights across various patient groups. 𝐒𝐞𝐜𝐮𝐫𝐞 𝐚𝐧𝐝 𝐀𝐜𝐜𝐮𝐫𝐚𝐭𝐞 𝐃𝐚𝐭𝐚 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬: The method ensures high data security while enhancing prediction accuracy, analyzing patient data without moving it from its original location. How do you envision integrating these advancements into your practice? What challenges do you face in treating rare cancers that this technology could address? The best place for us to have this chat is at Healthcare Innovators Connect, an invite-only meeting to dive deeper into these groundbreaking developments! Our scientific team initiates conversations that 𝐝𝐫𝐢𝐯𝐞 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧. We will give you this: exclusive discussions, access to industry leaders, and collaboration opportunities. Drop me a message for an invite to our next session. All sessions will stay invite-only. P.S. If you've read this far, we know you're motivated to make impactful changes with us. Feel free to ask me more about it! #𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 #𝐃𝐫𝐢𝐯𝐞𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐂𝐚𝐫𝐞 #𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐨𝐫𝐬𝐂𝐨𝐧𝐧𝐞𝐜𝐭 #𝐈𝐏𝐓𝐋𝐟𝐫𝐨𝐦𝐒𝐢𝐧𝐠𝐚𝐩𝐨𝐫𝐞 #𝐀𝐒𝐂𝐎2024